Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Cash from Operations (2017 - 2025)

Arcus Biosciences has reported Cash from Operations over the past 9 years, most recently at 120000000.0 for Q4 2025.

  • Quarterly results put Cash from Operations at 120000000.0 for Q4 2025, down 20.0% from a year ago — trailing twelve months through Dec 2025 was 482000000.0 (down 183.53% YoY), and the annual figure for FY2025 was 482000000.0, down 183.53%.
  • Cash from Operations for Q4 2025 was 120000000.0 at Arcus Biosciences, down from 97000000.0 in the prior quarter.
  • Over the last five years, Cash from Operations for RCUS hit a ceiling of 654000000.0 in Q1 2022 and a floor of 133000000.0 in Q2 2025.
  • Median Cash from Operations over the past 5 years was 71997500.0 (2021), compared with a mean of 38800000.0.
  • Biggest five-year swings in Cash from Operations: surged 1086.19% in 2022 and later crashed 6500.0% in 2025.
  • Arcus Biosciences' Cash from Operations stood at 61932000.0 in 2021, then fell by 13.03% to 70000000.0 in 2022, then fell by 25.71% to 88000000.0 in 2023, then dropped by 13.64% to 100000000.0 in 2024, then decreased by 20.0% to 120000000.0 in 2025.
  • The last three reported values for Cash from Operations were 120000000.0 (Q4 2025), 97000000.0 (Q3 2025), and 133000000.0 (Q2 2025) per Business Quant data.